Safety Study of ALG- 1001 to Treat Diabetic Macular Edema
Status:
Withdrawn
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and efficacy of ophthalmic intravitreal
injection of ALG - 1001 in human subjects with diabetic macular edema. The primary endpoint
of this study is observation of dose limiting toxicity and maximum tolerated dose. The
secondary endpoint of this study is observation of a clinical effect in BCVA (ETDRS letters)
and OCT central macular thickness.